Gemeinschaftpraxis Dres. Med Blersch/Redelstein
- Address
- lock Available on a paid plan
Gemeinschaftpraxis Dres. Med Blersch/Redelstein - Neurology and Psychiatry Research Center
Gemeinschaftpraxis Dres. Med Blersch/Redelstein is a specialized medical research practice dedicated to advancing treatments in neurological and psychiatric disorders. The center demonstrates expertise in conducting complex clinical trials evaluating both innovative biosimilar therapies and novel pharmaceutical interventions for central nervous system conditions.
- Relapsing-remitting multiple sclerosis biosimilar development and pharmacokinetic studies
- Major depressive disorder treatment research, focusing on mild to moderate severity cases
- Pharmacodynamic assessments and clinical efficacy evaluations in neuropsychiatric conditions
The practice has particular expertise in multiple sclerosis research, including sophisticated studies comparing biosimilar products through comprehensive pharmacokinetic and pharmacodynamic assessments, as well as brain lesion monitoring. Additionally, the center conducts research in psychiatric disorders, specifically investigating alternative therapeutic approaches for major depressive disorder using validated assessment tools such as the Montgomery-Åsberg Depression Rating Scale to measure treatment efficacy and clinical outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Amgen Inc.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Gemeinschaftpraxis Dres. Med Blersch/Redelstein
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Comparative Study of Pharmacokinetics, Pharmacodynamics, and Safety of ABP 692 and Ocrelizumab in Relapsing-Remitting Multiple Sclerosis | Amgen Inc. | Phase III | Not Yet Recruiting | Sep 2025 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Lavender Oil | 1 | Unknown | 2025-11-17 | 2025-11-17 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.